Brentuximab for Refactory Hodgkin’s Lymphoma: A Case Report

Edris Sadeghi¹ and Mehrdad Payandeh^2,

¹Department of Nursing, Borujerd Branch, Islamic Azad University, Borujerd, Iran

²Department of Hematology and Medical Oncology, Kermanshah University of Medical Sciences, Kermanshah, Iran

Cite this paper:
Edris Sadeghi and Mehrdad Payandeh. Brentuximab for Refactory Hodgkin’s Lymphoma: A Case Report. American Journal of Cancer Prevention. 2017; 5(3):39-40. doi: 10.12691/ajcp-5-3-4

Abstract

Hodgkin's lymphoma (HL) continues to be an intriguing, and fascinating lymphoma [1]. HL is expected to cure the majority of patients. Brentuximab vedotin is a CD30 antibody. We survey efficacy of brentuximab in patient with HL who was resistant to treatment. A 43 year old male referred with cough and right supraclavicular lymphadenopathy. His disease was HL, nodular sclerosis type (stage IIB and grade II) with megakaryocytosis in bone marrow aspiration (BMB). He was treated with 6 cycles of induction chemotherapy including adriamycin, bleomycin, vinblastine and dacarbazine (ABVD) and achieved a complete remission by imaging assessment. Then he received ifosfamide, carboplatin, etoposide (ICE) plus brentuximab vedotin (1.8 mg/kg every 3 weeks) regimen for 6 courses. At the end of this time he been eligible for autologous bone marrow transplantation (BMT). Bone marrow was done and after 13 days with good engraftment the patient discharge hospital. Therapists should be try with a specific target when they need a new and potent treatment like BMT for an active disease. Brentuximab vendotin is a new drug in policy of recurrence that it used for a few of cases in Iran.

Keywords:
ABVD BMT brentuximab Hodgkin's Lymphoma

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References:

[1]	Classics in oncology. Excerpts from: On some morbid appearances of the absorbent glands and spleen, Thomas Hodgkin. CA Cancer J Clin. 1973; 23(1):54-60.
[2]	Skoetz N, Trelle S, Rancea M, Haverkamp H, Diehl V, Engert A, Borchmann P. Effect of initial treatment strategy on survival of patients with advanced-stage Hodgkin's lymphoma: a systematic review and network meta-analysis. The Lancet Oncology. 2013; 14(10): 943-952.
[3]	S Horning MF, S DeVos, P Borchmann, T Illidge, A Engert, S Arai AY, S Horning, M Fanale. Defining a population of Hodgkin lymphoma patients for novel therapeutics: an international effort. Annals of Oncology. 2008; 20, article 118.
[4]	Younes A, Bartlett NL, Leonard JP, Kennedy DA, Lynch CM, Sievers EL, Forero-Torres A. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med. 2010; 363(19): 1812-21.
[5]	Peipei Xu, Fan Wang, Chaoyang Guan, Jian Ouyang, Xiaoyan Shao, and Bing Chen. A case report and literature review of primary resistant Hodgkin lymphoma: a response to anti-PD-1 after failure of autologous stem cell transplantation and brentuximab vedotin. Onco Targets Ther. 2016; 9: 5781-5789.
[6]	Dumaswala K, Mehta A. Novel agents for the treatment of Hodgkin lymphoma. Exp Rev Hematol. 2015; 8(5): 659-667.